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Barriers to Receipt of Prenatal Tetanus Toxoid, Reduced Diphtheria Toxoid, and 
Acellular Pertussis Vaccine Among Mothers of Infants Aged <4 Months 
with Pertussis — California, 2016
Sarah New, MPH1; Kathleen Winter, PhD1,2, Rebeca Boyte, MAS1; Kathleen Harriman, PhD1; Anya Gutman, MPH1;  
Amber Christiansen, MPH1; Sarah Royce, MD1
Vaccination with tetanus toxoid, reduced diphtheria tox-
oid, and acellular pertussis (Tdap) vaccine is recommended 
for all pregnant women to protect infants who are too young 
for vaccination from severe pertussis-related outcomes (1–3). 
However, Tdap vaccine coverage among pregnant women 
remains suboptimal in California (4). California mothers 
whose infants developed pertussis in 2016 and their prenatal 
care providers were interviewed to ascertain possible reasons for 
low Tdap vaccine coverage. Mothers who were offered Tdap 
vaccination on-site during a routine prenatal visit were more 
likely to be vaccinated than were mothers who were referred 
off-site for vaccination. Mothers insured by Medicaid were 
less likely to receive Tdap vaccine than were mothers with 
private insurance, even when the vaccine was stocked on-site. 
Nearly all vaccinated mothers received Tdap vaccine in their 
prenatal clinic. Incorporating Tdap vaccination into routine 
prenatal care visits is an effective means to increase prenatal 
Tdap vaccination coverage.
Most severe and fatal cases of pertussis occur in infants who 
have not yet started the primary pertussis vaccination series. To 
reduce the incidence of pertussis in these young infants, the 
Advisory Committee on Immunization Practices (ACIP) recom-
mends that pregnant women receive Tdap vaccine at the earliest 
opportunity, during 27–36 weeks’ gestation of each pregnancy 
(3). Vaccination during this period results in optimal transpla-
cental transfer of maternal pertussis antibodies, which provides 
infants with passive protection against pertussis during the first 
weeks of life (1–3). Despite this recommendation, prenatal Tdap 
vaccine coverage in California remains low, with 52% of preg-
nant women estimated to have been vaccinated, and coverage 
is even lower (40%) among women with Medicaid insurance 
(5). In 2016, a low-incidence pertussis year in California, 114 
pertussis cases, which included two pertussis-related deaths, 
occurred among infants aged <4 months.
California local health department personnel completed a 
case report form and attempted to complete a supplemental 
questionnaire using information collected during routine case 
investigation interviews with mothers of all 114 infants aged 
<4 months with pertussis who had illness onset during 2016. 
Interviewed mothers were asked to identify their prenatal care 
provider; whether they received a recommendation for Tdap 
vaccination during pregnancy with the case infant; whether 
they received Tdap vaccine; and if so, the date and location 
it was administered. Mothers who reported that they did not 
receive Tdap vaccine during pregnancy were asked why Tdap 
vaccine was not administered. Prenatal care providers were 
asked to identify the mothers’ insurance type during preg-
nancy; whether Tdap vaccination was recommended during 
pregnancy; whether Tdap vaccine was stocked in the clinic; 
and if not, why it was not stocked. Providers were also asked 
to verify the mothers’ Tdap vaccination status, and if Tdap 
vaccine was administered, the date and gestational week of 
administration. If mothers were referred off-site for Tdap 
vaccination, providers were asked whether they followed up 
to ensure that Tdap vaccination occurred. In addition, the 
California Immunization Registry was searched in an attempt 
to identify doses of Tdap vaccine that were not reported dur-
ing interviews. However, this registry was mandated in late 
2016 for pharmacists only. Additional variables collected 
from infant pertussis case reports included whether the infant 
was hospitalized or admitted to an intensive care unit (ICU) 
and the infant’s outcome. Relative risks and 95% confidence 
intervals (CIs) were calculated to identify differences between 
vaccinated and unvaccinated mothers and barriers to receipt 
of prenatal Tdap vaccine. Because reporting of pertussis cases 
in infants aged <4 months is mandated in California, the 
follow-up interviews and data collected for this analysis were 
considered to be nonresearch data.
Sixty-six (58%) mothers and their prenatal care providers 
completed the supplemental questionnaire during routine case 
investigations. Data on mother’s insurance status, stocking 
status of Tdap vaccine by provider, or mother’s gestational 
week of pregnancy (if vaccinated) were incomplete for six 
(9%) mothers and were excluded from relevant calculations. 
Twenty-six (39%) of the 66 interviewed mothers reported 
receiving Tdap vaccine during their pregnancy with the case 
infant; among these, 24 (92%) were vaccinated at their prenatal 
care provider’s office. Prenatal care providers documented Tdap 
vaccine administration for 25 of the 26 mothers who reported 
vaccination; no information on a Tdap vaccine dose was found 
in the medical record or the California Immunization Registry 
for one mother. Among the 25 mothers with documentation 
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of receipt of prenatal Tdap vaccine, 20 (80%) were vaccinated 
according to ACIP recommendations, during 27–36 weeks’ 
gestation (median = 32 weeks). Five (20%) mothers received 
Tdap vaccine outside the recommended 27–36 week time 
frame (one each at 26, 38, and 39 weeks’ gestation and two 
at 37 weeks). Among the 20 infants whose mothers were 
vaccinated during the recommended time frame, four were 
hospitalized, but none required admission to an ICU. Among 
the five infants whose mothers were vaccinated outside the 
recommended time frame, two were hospitalized, including 
one who required ICU admission and subsequently died.
Among the 66 interviewed mothers, 40 (61%) did not 
receive Tdap vaccine during pregnancy and among these 
mothers, 20 (50%) of their infants were hospitalized, including 
eight (40%) who were admitted to an ICU, one of whom died. 
Among the 40 unvaccinated mothers, 10 (25%) did not receive 
a recommendation or referral off-site for vaccination from 
their prenatal care provider, nine (23%) were referred off-site 
for vaccination but did not receive Tdap vaccine, eight (20%) 
mothers reported refusing Tdap vaccine for personal reasons, 
seven (18%) were deferred for vaccination by their provider 
for a reason not considered by ACIP to be a contraindication 
(prior receipt of Tdap vaccine, minor illness, or current medi-
cation use), three (8%) did not receive prenatal care during 
27–36 weeks’ gestation, one (3%) reported a possible valid 
contraindication (adverse reaction to pertussis vaccination 
as a child), and no information was available for two (5%) 
women (6) (Table 1). Sixteen (40%) of the 40 mothers who 
were not vaccinated during pregnancy received Tdap vaccine 
postpartum (the recommended strategy before 2011).
Among the 60 (91%) mothers with complete information, 
19 (73%) of 26 women with private insurance and 15 (44%) 
of 34 women insured by Medicaid received prenatal care from a 
provider who stocked Tdap vaccine on-site (Table 2). Fourteen 
(54%) mothers with private insurance received Tdap vaccine 
on time, compared with six (18%) of mothers with Medicaid 
insurance. Mothers whose providers stocked Tdap vaccine 
on-site were significantly more likely to have been vaccinated 
(relative risk [RR] = 3.3; 95% CI = 1.9–5.5) than were mothers 
whose providers did not stock Tdap vaccine. Mothers insured 
by Medicaid were significantly less likely than those with pri-
vate insurance to receive prenatal Tdap vaccine (0.4; 0.2–0.8) 
or to receive prenatal Tdap vaccine during the appropriate 
time frame, even when it was stocked on-site (0.5; 0.3–1.1).
Among the 61 interviewed prenatal care providers whose 
Tdap vaccine stocking policies were known, 34 (56%) stocked 
Tdap vaccine on-site. Among the 27 (44%) providers who 
did not stock Tdap vaccine on-site, 17 (63%) recommended 
Tdap vaccine during pregnancy, 16 of whom referred mothers 
off-site for vaccination, typically to a pharmacy, local public 
health department, or the mother’s primary care physician. 
Two (13%) of the 16 mothers referred off-site were vaccinated, 
including one who was vaccinated at 38 weeks’ gestation. In 
only one case was the Tdap dose documented in the mother’s 
medical record. Among the 27 providers who did not stock 
Tdap vaccine on-site, the most common reasons cited for not 
stocking were cost (44%) and reimbursement (41%) issues.
Discussion
In this review of 66 mothers of infants aged <4 months who 
became ill with pertussis in 2016, 20 mothers (30%) received 
Tdap vaccine during the time frame recommended by ACIP, all 
of whom were vaccinated in their prenatal clinic during a rou-
tine visit. Mothers whose providers stocked Tdap on-site were 
more likely to be vaccinated than were those whose providers 
did not stock Tdap. This finding is consistent with a previ-
ous survey demonstrating that receipt of influenza vaccine by 
pregnant women was more likely among those whose prenatal 
TABLE 1. Reasons prenatal Tdap vaccination was not received during 
pregnancy among interviewed mothers of infants aged <4 months 
with pertussis (N = 40) — California, 2016
Reason No. (%)
No recommendation or referral 10 (25)
Referred off-site, did not follow up 9 (23)
Refused for personal reasons 8 (20)
Invalid contraindication* 7 (18)
No prenatal care in third trimester 3 (8)
Valid contraindication 1 (3)
Unknown 2 (5)
Abbreviation: Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine.
* Invalid contraindications included prior receipt of prenatal Tdap (two); minor 
illness (two); previous illness associated with receipt of influenza vaccine (one); 
family member up to date with pertussis vaccination (one); and current 
medication use (one).
TABLE 2. Prenatal Tdap vaccination outcomes for interviewed 
mothers of infants aged <4 months with pertussis (N = 60*), by clinic 
Tdap vaccine stocking policy and mothers’ insurance coverage — 
California, 2016
Tdap policy/Insurance 
coverage
Tdap vaccination status 
no. (%)
Received per ACIP 
recommendations†
Not received on  
time or at all
Tdap stocked on-site in clinic (n = 34)
Private insurance (n = 19) 14 (41) 5 (15)
Medicaid (n = 15) 6 (18) 9 (26)
Tdap not stocked on-site in clinic (n = 26)
Private insurance (n = 7) 0 (—) 7 (27)
Medicaid (n = 19) 0 (—) 19 (73)
Unknown (n = 5) 0 (—) 5 (100)
Abbreviations: ACIP  =  Advisory Committee on Immunization Practices; 
Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis.
* Six of the 66 mothers interviewed were excluded because data on mother’s 
insurance status, stocking status of Tdap vaccine by provider, or mothers’ 
gestational week of pregnancy (if vaccinated) were incomplete.
† Among clinics that stocked Tdap vaccine on-site, 20 mothers received Tdap 
during 27–36 weeks’ gestation.
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care providers offered vaccination on-site (4). However, even 
when prenatal care providers stocked Tdap vaccine on-site, 
women insured by Medicaid were less likely to receive Tdap 
vaccination than were women with private insurance. Previous 
Tdap vaccination coverage estimates among pregnant women 
in California were also lower among those insured by Medicaid 
(40%) than among those with private insurance (65%) (5). 
Reasons for this disparity are not known; however, a need exists 
to reduce financial barriers to stocking and administering Tdap 
vaccine in prenatal clinics, particularly among those serving 
Medicaid patients.
To prevent pertussis among young infants, women should 
receive Tdap vaccination during 27–36 weeks’ gestation during 
every pregnancy. A recommendation by prenatal care provid-
ers for their pregnant patients to receive Tdap is important, 
particularly among providers who do not stock Tdap vaccine 
on-site. If Tdap vaccine is not stocked on-site, it is important 
to provide pregnant patients with specific information* about 
where they can receive Tdap vaccination and to follow up at 
subsequent visits to ensure Tdap vaccine is received within 
the recommended time frame (7,8). Approximately 40% of 
the unvaccinated mothers in this analysis never received a 
recommendation or referral for Tdap vaccine or were deferred 
for reasons that were inconsistent with current ACIP recom-
mendations, and 40% of the unvaccinated mothers, including 
one who originally refused Tdap vaccination, received Tdap 
vaccine postpartum, suggesting that prenatal-provider educa-
tion about current Tdap vaccine recommendations is needed. 
Eight (20%) of the 40 mothers who were not vaccinated during 
pregnancy refused prenatal Tdap.
Fewer infants of mothers who were vaccinated according to 
recommendations required hospitalization after developing 
pertussis than did infants of unvaccinated mothers. Although 
not statistically significant, this difference is consistent with a 
previous report and highlights the importance of prenatal Tdap 
vaccination in preventing severe outcomes of pertussis (9).
The findings in this report are subject to at least one limita-
tion. The relatively small sample size might affect the general-
izability of these findings to the U.S. population of pregnant 
women and their prenatal care providers.
In California, pharmacists are permitted to provide immu-
nizations, and all routinely recommended adult vaccines are 
covered by Medicaid when given in a provider’s office or in 
a pharmacy. Recent state regulations require pharmacists to 
notify providers of immunizations administered and to enter 
all doses into the California Immunization Registry, making 
it possible for providers to know whether vaccine referrals to 
* http://eziz.org/resources/pertussis-promo-materials/prenatal-tdap/.
pharmacies are successful. However, stocking vaccines on-site 
in prenatal clinics is the best way to ensure that all pregnant 
women are vaccinated and reduce the incidence of pertussis 
among infants too young to be vaccinated.
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Summary
What is already known about this topic?
Although tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis (Tdap) vaccination is recommended for all pregnant 
women during 27–36 weeks’ gestation to prevent infant 
pertussis, coverage among pregnant women is suboptimal.
What is added by this report?
Among 66 interviewed mothers of infants aged <4 months with 
pertussis, 30% appropriately received Tdap vaccine. Women 
whose clinics stocked Tdap vaccine were more likely to be 
vaccinated. Women with Medicaid were less likely to be 
vaccinated than were those with private insurance, even when 
treated in clinics that stocked Tdap vaccine.
What are the implications for public health practice?
Promoting on-site prenatal vaccination, educating providers 
about Tdap recommendations, and strengthening off-site referral 
likely will improve Tdap vaccination coverage during pregnancy.
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